Прастерон: Медициналық қолданысы мен қауіптері

Medical usage of the prasterone compound
DHEA as a medication or supplement

Prasterone is sometimes used as an androgen in menopausal hormone therapy. In addition to prasterone itself, a long lasting ester prodrug of prasterone, prasterone enanthate, is used in combination with estradiol valerate for the treatment of menopausal symptoms under the brand name Gynodian Depot. The current evidence of any benefit of DHEA supplementation to menopausal and postmenopausal women is inconclusive. Whereas prasterone (DHEA) supplementation in postmenopausal women can lead to an increase in E1, E2, testosterone, DHEA, and DHEAS serum levels, and a reduction in SHBG; still, the current evidence regarding the benefits of DHEA supplementation in postmenopausal women is inconclusive—while some studies suggest potential benefits, such as improved well being, sexual function, and possibly decreased menopausal symptoms, these findings are not universally agreed upon. Moreover, the long term safety data for DHEA supplementation is lacking, which is a significant concern. This is particularly relevant given that DHEA supplementation can lead to increased estrogenic availability, which could potentially have implications for conditions sensitive to hormonal levels. The mechanism of action of prasterone for this indication is unknown, though it may involve local metabolism of prasterone into androgens and estrogens. an ester prodrug of prasterone, prasterone is used in Japan as an injection for the treatment of insufficient cervical ripening and cervical dilation during childbirth.

Prasterone was previously marketed as a pharmaceutical medication under the brand name Diandrone in the form of a 10 mg oral tablet in the United Kingdom.

Prasterone is produced naturally in the human body, but the long term effects of its use are largely unknown. Another study utilized a dose up to 400 mg/day for 8 weeks with few adverse events reported. A longer term study followed patients dosed with 50 mg of prasterone for 12 months with the number and severity of side effects reported to be small. Another study delivered a dose of 50 mg of prasterone for 10 months with no serious adverse events reported. As a hormone precursor, there have been reports of side effects possibly caused by the hormone metabolites of prasterone. It is not known whether prasterone is safe for long term use. Some researchers believe prasterone supplements might actually raise the risk of breast cancer, prostate cancer, heart disease, diabetes,

Prasterone is possibly unsafe for individuals experiencing pregnancy, breastfeeding, hormone sensitive conditions, liver problems, diabetes, depression or mood disorders, polycystic ovarian syndrome (PCOS), or cholesterol problems. Prasterone has been reported to possess few or no side effects even at very high dosages (e. g., 50 times the recommended over the counter supplement dosage). However, it may cause masculinization and other androgenic side effects in women and gynecomastia and other estrogenic side effects in men. Prasterone is metabolized into androgens and estrogens in the body, including androstenedione, testosterone, estrone, estradiol, and estriol.

Prasterone is also reversibly transformed into its active metabolite Interconversion takes place in both adrenal and peripheral tissues. Although prasterone can reliably increase testosterone levels in women, this isn't similarly the case in men. In people with adrenal insufficiency, oral dosages of 20 to 50 mg/day prasterone have been found to restore DHEA and DHEA S levels to physiological levels seen in young healthy adults.

Prasterone is used medically as the C3β esters prasterone enanthate and prasterone sulfate. The 5α reduced and δ1 (1(2) dehydrogenated) analogue of prasterone is 1 dehydroepiandrosterone (1 DHEA or 1 androsterone), which is a prohormone of 1 testosterone (δ1 DHT or dihydroboldenone). Fluasterone (3β dehydroxy 16α fluoro DHEA) is a derivative of prasterone with minimal or no hormonal activity but other biological activities preserved. The combination of 4 mg estradiol valerate and 200 mg prasterone enanthate in an oil solution was introduced for use in menopausal hormone therapy by intramuscular injection under the brand name Gynodian Depot in Europe by 1978. In the early 1980s, prasterone became available and was widely sold over the counter as a non prescription supplement in the United States, primarily as a weight loss aid. It was described as a "miracle drug", with supposed anti aging, anti obesity, and anti cancer benefits. In 2001, Genelabs submitted a New Drug Application of prasterone for the treatment of systemic lupus erythematosus (SLE) to the FDA. This was the first prasterone containing medication to be approved by the FDA in this country. while its generic name is prasteronum in Latin, prastérone in French and its French popular name, and prasteron in German. In 1996, reporter Harry Wessel of the Orlando (Florida) Sentinel wrote about DHEA that "Thousands of people have gotten caught up in the hoopla and are buying the stuff in health food stores, pharmacies and mail order catalogs" but that "such enthusiasm is viewed as premature by many in the medical field." He noted that "National publications such as Time, Newsweek and USA Today have run articles recently about the hormone, while several major publishers have come out with books touting it." His column was widely syndicated and reprinted in other U. S. newspapers. The product was being "widely marketed to and used by bodybuilders," Dr. Paul Donahue wrote in 2012 for King Features syndicate.

In Australia, a prescription is required to buy prasterone, where it is also comparatively expensive compared to off the shelf purchases in US supplement shops. Australian customs classify prasterone as an "anabolic steroid[s] or precursor[s]" and, as such, it is only possible to carry prasterone into the country through customs if one possesses an import permit which may be obtained if one has a valid prescription for the hormone.

In Canada, prasterone is a Controlled Drug listed under Section 23 of Schedule IV of the Controlled Drugs and Substances Act and as such is available by prescription only.

Prasterone is listed as an anabolic steroid and is thus a class C controlled drug.

Prasterone is legal to sell in the United States as a dietary supplement. It is currently grandfathered in as an "Old Dietary Ingredient" being on sale prior to 1994. Prasterone is specifically exempted from the Anabolic Steroid Control Act of 1990 and 2004.

Prasterone is banned from use in athletic competition. which manages drug testing for Olympics and other sports. Yulia Efimova, who holds the world record pace for both the 50 meter and 200 meter breaststroke, and won the bronze medal in the 200 meter breaststroke in the 2012 London Olympic Games, tested positive for prasterone in an out of competition doping test. Rashard Lewis, then with the Orlando Magic, tested positive for prasterone and was suspended 10 games before the start of the 2009–10 season. In 2016 MMA fighter Fabio Maldonado revealed he was taking prasterone during his time with the UFC. In January 2011, NBA player O. J. Mayo was given a 10 game suspension after testing positive for prasterone. Mayo termed his use of prasterone as "an honest mistake," saying the prasterone was in an over the counter supplement and that he was unaware the supplement was banned by the NBA. Mayo was the seventh player to test positive for performance enhancing drugs since the league began testing in 1999. Olympic 400 meter champion Lashawn Merritt tested positive for prasterone in 2010 and was banned from the sport for 21 months. Tennis player Venus Williams had permission from the International Tennis Federation to use DHEA along with hydrocortisone as a treatment for "adrenal insufficiency," but it was revoked in 2016 by the World Anti Doping Agency, which believed DHEA use would enhance Williams' athletic performance.

A meta analysis of intervention studies shows that prasterone supplementation in elderly men can induce a small but significant positive effect on body composition that is strictly dependent on prasterone conversion into its bioactive metabolites such as androgens or estrogens. Evidence is inconclusive in regards to the effect of prasterone on strength in the elderly. In middle aged men, no significant effect of prasterone supplementation on lean body mass, strength, or testosterone levels was found in a randomized placebo controlled trial.

There is no evidence prasterone is of benefit in treating or preventing cancer. Prasterone may enhance G6PD mRNA expression, confounding its inhibitory effects.

There is some evidence of short term benefit in those with systemic lupus erythematosus but little evidence of long term benefit or safety. Prasterone was under development for the treatment of systemic lupus erythematosus in the United States and Europe in the 1990s and 2000s and reached phase III clinical trials and preregistration for this indication, respectively, but ultimately development was not continued past 2010.

Prasterone supplementation has not been found to be useful for memory function in normal middle aged or older adults. It has been studied as a treatment for Alzheimer's disease, but there is no evidence that it is effective or ineffective. More research is needed to determine its benefits.

A few small, short term clinical studies have found that prasterone improves mood but its long term efficacy and safety, and how it compares to antidepressants, was unknown as of 2015.